Compare MORN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | IBRX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.5B |
| IPO Year | 2004 | 2015 |
| Metric | MORN | IBRX |
|---|---|---|
| Price | $170.10 | $8.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $256.50 | $12.57 |
| AVG Volume (30 Days) | 512.2K | ★ 11.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | 3.38 | ★ 38.71 |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $2,445,500,000.00 | $113,288,000.00 |
| Revenue This Year | $9.14 | $88.59 |
| Revenue Next Year | $7.23 | $131.15 |
| P/E Ratio | $63.22 | ★ N/A |
| Revenue Growth | 7.49 | ★ 668.31 |
| 52 Week Low | $149.08 | $1.95 |
| 52 Week High | $316.71 | $12.43 |
| Indicator | MORN | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 55.86 |
| Support Level | $162.56 | $7.77 |
| Resistance Level | $190.99 | $8.51 |
| Average True Range (ATR) | 7.34 | 0.58 |
| MACD | -0.19 | 0.03 |
| Stochastic Oscillator | 40.66 | 76.86 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.